COO Cooper Companies (The)
FY2025 10-K
Cooper Companies (The) (COO) filed its fiscal year 2025 10-K annual report with the SEC on Dec 5, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: global medical device company with two segments, CooperVision and CooperSurgical, focused on vision, fertility, and women’s health
- • Expanded geographic reach, selling products in over 130 countries
Management Discussion & Analysis
- • Outlook optimistic on long-term contact lens and general health care market growth
- • Risks and uncertainties acknowledged in global operating environment
Risk Factors
- • Regulatory risk: FDA and NMPA approvals for MiSight 1 day lens to slow myopia progression in children aged 8-12, critical for market penetration in US, China, and Japan
- • Macroeconomic exposure: 5% net sales growth in Americas and 8% in EMEA, driven by silicone hydrogel lenses, with revenue positively impacted by $16 million favorable foreign exchange in 2025
Financial SummaryXBRL
Revenue
$4.1B
Net Income
$375M
Gross Margin
65.5%
Operating Margin
16.7%
Net Margin
9.2%
ROE
4.6%
Total Assets
$12.4B
EPS (Diluted)
$1.87
Operating Cash Flow
$796M
Source: XBRL data from Cooper Companies (The) FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cooper Companies (The)
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.